Sale of Shares of Plasma Resources UK Limited

Sale of Shares of Plasma Resources UK Limited

The Department has appointed Lazard and Co Limited (“Lazard”) to act as its exclusive financial advisor in this process and is inviting expressions of interest through the submission of non-binding indicative offers (“Indicative Offers”) in relation to the Proposed Transaction.

UK-London: Call for Expression of Interest in the sale of shares of Plasma Resources UK Limited (“PRUK” or the “Company”)

2013/S 020-031538

UK

Tender notice

UK’s Department of Health, London, UNITED KINGDOM

PRUK is a wholly owned company of the UK’s Department of Health (“Department”) that holds two related companies:

1. DCI Biologicals, Inc. (“DCI”), a US based company that collects plasma; and

2. Bio Products Laboratory Limited (“BPL”) based in Elstree, near Watford, England, which processes the plasma to produce a range of therapeutic products.

Disposal of the majority or all of the issued shares in PRUK

The Department, as the sole shareholder, has decided to seek private sector investment in PRUK through the sale of the majority or all of the issued share capital in the Company (the “Proposed Transaction”).

The Department has appointed Lazard & Co Limited (“Lazard”) to act as its exclusive financial advisor in this process and is inviting expressions of interest through the submission of non-binding indicative offers (“Indicative Offers”) in relation to the Proposed Transaction.

The Department has carefully examined the strategic option that will best allow the Company to grow and be successful in an established and highly competitive global industry.

The Department intends to consider only those Indicative Offers which show not just the level of resource they are willing to make available but also set out a credible plan as to how the operations will be grown and the products developed.

Submission of Indicative Offers

Further information in relation to the process and requirements needed for an Indicative Offer can be obtained from Lazard. Any interested party wishing to submit an Indicative Offer will need to have signed a legally binding confidentiality agreement which is available from Lazard. Contact details for Lazard are set out at the end of this Tender Notice.

Disclaimer and Other Matters

Neither the Department nor Lazard nor any member of the Lazard Group (collectively, “us” or “we”) will be under any obligation to accept, review or consider any proposal or offer submitted and are not under any obligation to accept any offer at all. We expressly reserve the right, without advance notice and without giving reasons, at any time and in any respect to negotiate with one or more parties and/ or to accept any offer and/ or to change the procedure for the sale of PRUK or to terminate discussions with any other prospective buyer prior to the signing of a binding agreement.

The issuance of this Tender Notice does not form any commitment to proceed with the Proposed Transaction as contemplated by this Tender Notice. In no circumstances will we be responsible for any professional fees, costs or expenses incurred in connection with your possible acquisition of PRUK, including, without limitation, any costs and expenses incurred in your evaluation of PRUK or preparation of any Indicative Offer or any subsequent bid. We shall have no liability whatsoever in respect of this Tender Notice or the matters contemplated herein and no representation or warranty, express or implied, is or will be made by us in respect of the contents of this Tender Notice or the matters arising out of it.

Under no circumstances should any prospective purchaser or its associates, advisers or agents communicate directly or indirectly with the management or employees of PRUK (or its subsidiaries) or with any other party (including, in particular, any third party who may trade from any of the sites or who may have contractual relationships with the Company) or any other potential purchaser of the Company in relation to the Proposed Transaction without the prior written consent of Lazard. Please be reminded that strict adherence to this provision is considered essential for your continued participation in the process. Any questions regarding the Company or the sale process should, in the first instance, be directed to Lazard.

Contact Details for Lazard

Please do not hesitate to contact Vasco Litchfield (+44 20 7187 2901, vasco.litchfield@lazard.com), Nicolas Serandour (+44 20 7187 2089, nicolas.serandour@lazard.com) or Matthew Knott (+44 20 7187 2604, matthew.knott@lazard.com) if you require any clarification with respect to this Tender Notice or the process in general.

Lazard, which is authorised and regulated in the United Kingdom by the Financial Services Authority, is acting for the Seller in connection with the Proposed Transaction and no-one else and will not be responsible to anyone other than the Seller for providing the protections afforded to clients of Lazard nor for providing advice in relation to the Proposed Transaction.

Enjoyed this post? Share it!